Molecular pathways and emerging therapeutic targets in the pathogenesis of diabetic kidney disease

Diabetic kidney disease (DKD) arises from intersecting metabolic, hemodynamic, inflammatory, and epigenetic programs that progressively remodel the glomerulus and tubulointerstitium on a molecular level. Hyperglycemia-driven AGE-RAGE signaling, PKC activation, and RAAS dysregulation converge on oxidative stress, endothelial dysfunction, and profibrotic transcription (e.g., TGF-beta/Smad), while mitochondrial and endoplasmic-reticulum stress amplify lipotoxicity and cell death. Innate immune activation (macrophage recruitment and inflammasome signaling) and maladaptive repair promote extracellular-matrix accumulation and nephron loss. Multi-omics studies further implicate durable chromatin and non-coding RNA changes that sustain metabolic memory despite improved glycemia. In this review, we synthesize landmark and recent mechanistic data spanning glomerular filtration barrier injury, tubular stress pathways, and immune-metabolic crosstalk, and we highlight therapeutic strategies that move upstream of symptom control. We discuss established disease-modifying agents (RAAS blockade, SGLT2 inhibitors, and non-steroidal MR antagonists) alongside investigational approaches including epigenetic modulators, AMPK/NAD + axis targeting, and gene/RNA-based interventions. Together, these advances frame DKD as a disorder of rewired signaling and gene-regulatory circuitry, where convergent molecular nodes across podocytes, endothelium, and tubules offer the actionable considerations for durable renal protection.